Evidence map›Paper›PMID 34523232›Full record

Trial reportThoracic cancer2021

Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402.

Eisaku Miyauchi, Hisashi Tanaka, Atsushi Nakamura, Toshiyuki Harada, Taku Nakagawa, Mami Morita, Daisuke Jingu, Tomoya Kuda, Shunichi Gamou, Ryota Saito and 1 more

Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 3 countries.

Eisaku MiyauchiDepartment of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan.ORCID 0000-0002-6837-6392
Hisashi TanakaDepartment of Respiratory Medicine, Hirosaki University Hospital, Hirosaki, Japan.ORCID 0000-0003-2009-0210
Atsushi NakamuraDepartment of Respiratory Medicine, Sendai Kosei Hospital, Sendai, Japan.
Toshiyuki HaradaDepartment of Respiratory Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.
Taku NakagawaDepartment of Thoracic Surgery, Omagari Kosei Medical Center, Omagari, Japan.
Mami MoritaDepartment of Respiratory Medicine, Miyagi Cancer Center, Natori, Japan.
Daisuke JinguDepartment of Respiratory Medicine, Saka General Hospital, Shiogama, Japan.
Tomoya KudaDepartment of Respiratory Medicine, Naha City Hospital, Naha, Japan.
Shunichi GamouDepartment of Respiratory Medicine, Kesennuma City Hospital, Kesennuma, Japan.
Ryota SaitoDepartment of Respiratory Medicine, Tohoku University Hospital, Sendai, Japan.
Akira InoueDepartment of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.
Tohoku University Hospital · JPGeneral Hospital of Drama · GRHirosaki University Hospital · JPHokkaido hospital · JPMiyagi Prefectural Hospital Organization · JPNaha City Hospital · JPNumazu City Hospital · JPOffice of Multidisciplinary Activities · USSendai City Hospital · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin-bound paclitaxel (nab-PTX) in patients with advanced non-small cell lung cancer (NSCLC).

methodsThe study included patients aged ≥20 years with previously treated NSCLC. Nab-PTX (100-150 mg/m

resultsA total of 15 patients received biweekly nab-PTX (100-150 mg/m

conclusionsBiweekly nab-PTX monotherapy was well tolerated and exhibited favorable antitumor activity in patients with previously treated NSCLC.

Indexed as

AgedAged, 80 and overAlbuminsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungFemaleHumansLung NeoplasmsMaleMiddle AgedPaclitaxelPlatinumProgression-Free Survival130-nm albumin-bound paclitaxelAlbuminsPaclitaxelPlatinumnab-PTX monotherapynon-small cell lung cancerphase I/II trial

Identifiers

PMID34523232
PMCPMC8563146
OpenAlexW3201319284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.